Investor Relations

Micreos is a privately owned company, operating and expanding around the world. We believe our products provide a meaningful benefit to people in all countries, irrespective of regional boundaries, just as the dangerous bacteria killed by our compounds are not restricted by borders.

Contact:

Mark Offerhaus (CEO)

Nicolaas Weeda (Corporate Secretary & General Counsel)

Mark Offerhaus, CEO of the Dutch biotechnology company Micreos, presents Staphefekt against MRSA in Amsterdam on Nov.6, 2014

NEWS

Micreos appoints Joost Goderie as CFO and member of the Board of Directors

PRESS RELEASE The Hague, The Netherlands, January 28, 2022 - Micreos announced that it has ap ...

New clinical study proves safe anti-S. aureus endolysin ‘Staphefekt SA.100’ significantly reduces eczema symptoms

PRESS RELEASE - FOR IMMEDIATE RELEASE The Hague, December 7, 2021.A new study, published in t ...

Micreos appoints Matt Regan as CEO of its Pharmaceutical business

PRESS RELEASE The Hague, October 14, 2021 - Dutch biotechnology company Micreos has recr ...

Micreos secures 32 million for its endolysin-based platform as sustainable alternative to antibiotics

PRESS RELEASE THE HAGUE, The Netherlands, 30 September, 2021 - Dutch biotechnology company Mi ...

LOréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology

PRESS RELEASE Clichy / The Hague, 29 October 2020 – LOréal and Micreos anno ...

More news

© 2010 - MICREOS